Ultragenyx Pharmaceutical Inc banner

Ultragenyx Pharmaceutical Inc
NASDAQ:RARE

Watchlist Manager
Ultragenyx Pharmaceutical Inc Logo
Ultragenyx Pharmaceutical Inc
NASDAQ:RARE
Watchlist
Price: 22.84 USD 1.02% Market Closed
Market Cap: $2.2B

Wall Street
Price Targets

RARE Price Targets Summary
Ultragenyx Pharmaceutical Inc

Wall Street analysts forecast RARE stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for RARE is 57.68 USD with a low forecast of 25.25 USD and a high forecast of 126 USD.

Lowest
Price Target
25.25 USD
11% Upside
Average
Price Target
57.68 USD
153% Upside
Highest
Price Target
126 USD
452% Upside
Ultragenyx Pharmaceutical Inc Competitors:
Price Targets
JACK
Jack in the Box Inc
60% Upside
IBEX
Ibex Ltd
43% Upside
FSFG
First Savings Financial Group Inc
-1% Downside

Revenue
Forecast

N/A
Past Growth
26% / Year
Estimated Growth
Estimates Accuracy
0%
Average Miss
N/A
Past Growth
26% / Year
Estimated Growth
Estimates Accuracy
0%
Average Miss

The compound annual growth rate of Ultragenyx Pharmaceutical Inc's revenue for the next 3 years is 26%.

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
1%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
1%
Average Beat

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-50%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-50%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is RARE's stock price target?
Price Target
57.68 USD

According to Wall Street analysts, the average 1-year price target for RARE is 57.68 USD with a low forecast of 25.25 USD and a high forecast of 126 USD.

What is Ultragenyx Pharmaceutical Inc's Revenue forecast?
Projected CAGR
26%

The compound annual growth rate of Ultragenyx Pharmaceutical Inc's revenue for the next 3 years is 26%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett